Not Yet Recruiting PHASE2 INTERVENTIONAL 3-arm NCT05983094

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center

Conditions Breast Cancer Neoadjuvant Therapy

Interventions Carboplatin Epirubicin Pertuzumab Trastuzumab Utidelone

Updated 4 times since 2023 Last updated: Aug 1, 2023 Started: Sep 1, 2023 Primary completion: Sep 1, 2026 Completion: Sep 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05983094, this PHASE2 trial focuses on Breast Cancer and Neoadjuvant Therapy and remains actively recruiting participants. Sponsored by Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center, it has been updated 4 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Jul 2025 — Present [monthly]

Not Yet Recruiting PHASE2
Sep 2024 — Jul 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Sep 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Chinese Academy of Medical Sciences
First Affiliated Hospital of China Medical University

Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China